Accepted Manuscript Title: Bavituximab Plus Paclitaxel and Carboplatin for the Treatment of Advanced Non–Small-Cell Lung Cancer Author: Raghunadharao Digumarti P.P. Bapsy Attili V. Suresh G.S. Bhattacharyya Lokanatha Dasappa Joseph Shan David E. Gerber PII: DOI: Reference:
S0169-5002(14)00355-9 http://dx.doi.org/doi:10.1016/j.lungcan.2014.08.010 LUNG 4673
To appear in:
Lung Cancer
Received date: Revised date: Accepted date:
12-3-2014 13-8-2014 14-8-2014
Please cite this article as: Digumarti R, Bapsy PP, Suresh AV, Bhattacharyya GS, Dasappa L, Shan J, Gerber DE, Bavituximab Plus Paclitaxel and Carboplatin for the Treatment of Advanced NonndashSmall-Cell Lung Cancer, Lung Cancer (2014), http://dx.doi.org/10.1016/j.lungcan.2014.08.010 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Bavituximab Plus Paclitaxel and Carboplatin for the Treatment of
2
Advanced Non–Small-Cell Lung Cancer
ip t
1
3
Raghunadharao Digumarti, MD;1 P.P. Bapsy, MD;2 Attili V. Suresh, MD;3 G.S.
5
Bhattacharyya, MD;4 Lokanatha Dasappa, MD;5 Joseph Shan, MPH;6 David E.
6
Gerber, MD,7
7
1
8
Bangalore, India; 3Yashoda Hospital, Hyderabad, India; 4Orchid Nursing Home,
9
Kolkata, India; 5Kidwai Memorial Institute of Oncology, Bangalore, India; 6
an
us
cr
4
M
Nizam’s Institute of Medical Sciences, Hyderabad, India; 2Apollo Hospitals,
Peregrine Pharmaceuticals, Inc., Tustin, CA; 7UT Southwestern Medical
11
Center, Dallas, TX;
14 15 16 17 18
te Ac ce p
12 13
d
10
Address for Correspondence: Joseph Shan, MPH
Peregrine Pharmaceuticals, Inc. 14282 Franklin Avenue
Tustin, California 92780 Tel: (714) 508-6000
19
Fax: (714) 734-1692
20 21
[email protected] 1
Page 1 of 33
Abstract
24
Objective:
25
Bavituximab is a phosphatidylserine (PS)-targeting monoclonal antibody with
26
immune-modulating and tumor-specific vascular targeting properties.
27
Preclinical studies have shown activity against numerous solid tumors and at
28
least an additive effect in combination with chemotherapy. This study
29
evaluated bavituximab in combination with paclitaxel and carboplatin in
30
patients with previously untreated, locally advanced or metastatic non–small-
31
cell lung cancer (NSCLC).
32
Patients and Methods:
33
This phase II, open-label study (NCT00687817) was conducted in 49 patients
34
38 39
Results:
35 36 37
te
d
M
an
us
cr
ip t
23
Ac ce p
22
with stage IIIB/IV NSCLC utilizing a Simon two-stage design. Patients were treated with up to six cycles of carboplatin area under the concentration-time curve (AUC) 5 plus paclitaxel 175 mg/m2 every 21 days with weekly bavituximab 3 mg/kg followed by bavituximab monotherapy until progression or unacceptable toxicity.
2
Page 2 of 33
The primary efficacy endpoint of overall response rate (ORR) was 40.8%
41
(complete response [CR] 2.0%, partial response [PR] was 38.8%). Median
42
progression-free survival (PFS) and overall survival (OS) were 6.0 and 12.4
43
months, respectively. Treatment-related adverse events (AEs) occurred in
44
40.8% of patients. The most common treatment-related AEs were anemia
45
(10.2%), asthenia, vomiting, paresthesia, anorexia, and fatigue (6.1% each).
46
One patient with a central, cavitating squamous tumor developed fatal
47
hemoptysis and aspiration.
48
Conclusion:
49
Bavituximab in combination with paclitaxel-carboplatin as first-line therapy
50
demonstrated a tolerable safety profile and potential efficacy in this single-arm
51
phase II trial in patients with advanced local or metastatic NSCLC.
52
Randomized trials with this regimen are in progress.
54 55
cr
us
an M
d
te
Ac ce p
53
ip t
40
ClinicalTrials.gov Identifier: NCT00687817
Keywords
56
bavituximab; non-small-cell lung cancer; immune modulation; monoclonal
57
antibody; phosphatidylserine; paclitaxel, carboplatin
58 3
Page 3 of 33
Introduction
59
To date, the addition of molecular targeted therapies to standard first-line
60
chemotherapy for advanced non-small-cell lung cancer (NSCLC) has yielded
61
only modest clinical benefit. Combining epidermal growth factor receptor
62
(EGFR) or vascular endothelial growth factor receptor (VEGFR) tyrosine
63
kinase inhibitors with platinum-doublet regimens does not improve survival [1,
64
2, 3, 4, 5, 6]. The anti-EGFR monoclonal antibody cetuximab increases
65
survival by approximately one month when added to cisplatin-vinorelbine, but
66
does not enhance outcomes when combined with carboplatin-paclitaxel [7, 8].
67
Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal
68
antibody, increases survival by two months when added to carboplatin-
69
paclitaxel but does not improve survival when added to cisplatin-gemcitabine
70
[9,10]. Despite encouraging phase II trial results, the vascular disrupting agent
72 73 74
cr
us
an
M
d
te
Ac ce p
71
ip t
58
ASA404 failed to enhance survival when added to carboplatin-paclitaxel in the phase III setting [11].
Immunotherapy has recently emerged as a promising treatment strategy for advanced NSCLC [12]. The ability of cancer cells to evade host immune
75
responses results in tumor development and progression. Immune checkpoint
76
inhibitors may counteract these immunosuppressive effects. Clinical trials with
77
immunotherapies alone or in combination with chemotherapy in patients with 4
Page 4 of 33
advanced NSCLC have explored the effects of immune checkpoint inhibitors
79
such as anti-cytotoxic T lymphocyte 4 (CTLA-4) antibodies, anti-programmed
80
death-1 (PD-1) antibodies, and anti-PD-ligand 1 (PD-L1) antibodies have been
81
conducted, yielding promising results [13,14,15].
82
Bavituximab is a novel phosphatidylserine (PS)-targeting monoclonal antibody
83
with immune and vascular modulating properties that represent a new approach
84
to cancer therapy. Underlying the tumor specificity of bavituximab is the
85
distribution of its molecular target, the anionic membrane phospholipid PS. In
86
normal cells, PS is relegated to the inner membrane leaflet, where it is not
87
available for binding by bavituximab [16]. In a solid tumor microenvironment,
88
hypoxia and other physiologic stresses lead to PS “flipping” to the outer
89
membrane leaflet of the tumor and tumor endothelial cells [17]. Bavituximab
90
binds to exposed PS molecules via the serum protein, β2-glycoprotein 1
92 93 94
cr
us
an
M
d
te
Ac ce p
91
ip t
78
(β2GP1) [18, 19].
Exposed PS exerts a potent immunosuppressive effect allowing tumors to evade immune detection. Specifically, exposed PS downregulates macrophage
secretion of tumor necrosis factor-α and interleukin-12, and upregulates
95
production of transforming growth factor-β and interleukin-10. These effects
96
suppress innate immunity, blocking the development of M1 macrophages,
97
dendritic cell maturation, antigen presentation to T-cells, and cytotoxic T-cell 5
Page 5 of 33
responses. Bavituximab binding to PS counteracts these immunosuppressive
99
processes and promotes proinflammatory pathways such as myeloid-derived
ip t
98
suppressor cells (MDSC) differentiation, M2 to M1 polarization, recruitment of
101
tumoricidal M1 macrophages, dendritic cell maturation, and antigen
102
presentation [20]. Separately, bavituximab binding to PS induces antibody-
103
dependent cellular cytotoxicity, resulting in tumor vessel destruction [19,21].
104
In a phase I monotherapy study in patients with advanced solid tumors,
105
bavituximab 3 mg/kg weekly was identified as the preferred dose based on
106
effective target binding and dose response considerations [22]. There is strong
107
biologic rationale to combine bavituximab with chemotherapy and other cancer
108
treatments. In preclinical cancer models, cytotoxic agents such as taxanes
109
increase the proportion of malignant vascular endothelial cells with exposed PS,
110
thereby increasing bavituximab binding [19]. As a result, the addition of
115
Ac ce p
te
d
M
an
us
cr
100
116
survival (OS) was 21.4 months [26].
111 112 113 114
bavituximab to conventional therapies such as chemotherapy, radiation, and hormonal agents, appears to provide synergistic effects in multiple models [19,21,23,24,25]. In a phase II trial of docetaxel plus bavituximab in locally advanced or metastatic breast cancer, radiographic response rate was 61%, median progression-free survival (PFS) was 7.4 months, and median overall
6
Page 6 of 33
Based on unmet clinical need, biologic rationale, and encouraging safety and
118
efficacy data in other disease contexts, we performed a single-arm phase II trial
119
of bavituximab plus paclitaxel-carboplatin in patients with previously untreated,
120
locally advanced or metastatic NSCLC.
121
Patients and Methods
122
Study Design
123
This phase II, open-label, multicenter, non-randomized study (NCT00687817)
124
used a Simon two-stage design. If ≥4 of the 21 patients in stage 1 achieved a
125
radiographic response, 28 additional patients were to be enrolled in stage 2 for a
126
total of 49 patients (p0 = 0.15, p1 = 0.3). The protocol was reviewed and
127
approved by the institutional review boards of all participating sites, and written
128
informed consent was obtained from patients before study initiation.
130 131 132 133 134
cr us an
M
d
te
Ac ce p
129
ip t
117
Patients aged ≥18 years with measurable stage IIIb (with pleural effusion) or stage IV NSCLC confirmed by histology or cytology, a life expectancy of ≥3 months, and Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 were eligible. Patients were also required to have adequate bone marrow, liver, and renal function, in addition to D-dimer ≤2 x ULN and New York Heart Association functional class I/II.
7
Page 7 of 33
Patients were excluded if they had a known history of bleeding diathesis or
136
coagulopathy, current evidence of clinically significant bleeding, a history of
137
thromboembolic events (not including central venous catheter-related
138
thrombosis >12 months ago), grade 2 or higher peripheral neuropathy,
139
symptomatic or clinically active central nervous system disease or metastatic
140
lesions, major surgery within 4 weeks of initiation of study therapy, were
141
pregnant or nursing, had uncontrolled intercurrent disease, a history of
142
cardiovascular disease, cardiac arrhythmia requiring treatment, a serious non-
143
healing wound, or a known chronic infection (eg, HIV or hepatitis).
144
Additionally, patients requiring oral or parenteral anticoagulants (not including
145
aspirin for cardiovascular prophylaxis), chronic daily treatment with
146
nonsteroidal anti-inflammatory drugs, or steroids were ineligible. Eligibility
147
related to thrombolic or hemorrhagic events reflected regulatory requirements
149 150 151 152
cr
us
an
M
d
te
Ac ce p
148
ip t
135
arising from hypothetical concerns of a clinical antiphospholipid antibody syndrome and from generally observed vascular targeting agent-related toxicities. In bavituximab clinical trials conducted to date, rates of thromboembolic or hemorrhagic events do not appear to exceed the background rate expected for these populations [21,27,28].
8
Page 8 of 33
Treatment
154
Enrolled patients received up to six cycles of chemotherapy with carboplatin
155
area under the concentration-time curve (AUC) of 5 and paclitaxel 175 mg/m2
156
every 21days combined with weekly intravenous (IV) infusions of bavituximab
157
3 mg/kg until disease progression or unacceptable toxicities. The slightly lower
158
dose compared to regimens routinely employed in North America and Western
159
Europe (eg, carboplatin AUC 6 and paclitaxel 200 mg/m2) reflect standard
160
practice in South Asia and other global regions [29]. No dose reductions of
161
conventional therapies have been required with the addition of bavituximab
162
across multiple trials, including combinations with docetaxel in NSCLC
163
(NCT01138163, NCT01999673), sorafenib in hepatocellular carcinoma
164
(NCT01264705), gemcitabine in pancreatic cancer (NCT01272791), and
165
capecitabine-based chemoradiation in rectal cancer (NCT01634685). Prior to
170
Ac ce p
te
d
M
an
us
cr
ip t
153
171
minutes after chemotherapy as IV infusion over 90 minutes.
166 167 168 169
each bavituximab infusion, patients were premedicated with a steroid and antihistamine regimen according to institutional practice to decrease the risk of infusion reaction. Patients receiving premedication for paclitaxel did not require additional corticosteroids on days when both chemotherapy and bavituximab were administered. Bavituximab was administered at least 30
9
Page 9 of 33
In the event of chemotherapy-related adverse events (AEs), the start date of a
173
new cycle was delayed up to 21 days from the completion of the prior cycle.
174
Chemotherapy dose reductions followed instructions in the package insert.
175
There were no bavituximab dose reductions.
176
Patients who completed six cycles of combination therapy with ongoing disease
177
control continued to receive weekly bavituximab monotherapy until disease
178
progression or unacceptable toxicities. Clinical and laboratory assessments
179
continued every 3 weeks, and tumor response was evaluated every 2 months
180
until progressive disease (PD). Survival data were collected every 3 months.
181
Study Endpoints
182
The primary endpoint of this study was overall response rate (ORR), defined as
183
complete response (CR) plus partial response (PR) using Response Evaluation
184
Criteria in Solid Tumors (RECIST version 1.0). Secondary endpoints included
186 187 188
cr
us
an
M d
te
Ac ce p
185
ip t
172
PFS, duration of response (DR), OS, and safety. Safety was assessed by analyses of AEs and serious adverse events (SAEs), ECOG performance status, and laboratory evaluations (ie, hematology, coagulation assays, D-dimer, urinalysis, and serum chemistry). These data were recorded for all patients who
189
received any study drug. AEs were graded for severity according to Common
190
Terminology Criteria for Adverse Events (CTCAE) version 3.0 and coded
10
Page 10 of 33
using the Medical Dictionary for Regulatory Activities version 8.1, and the
192
causal relationship of AEs to treatment was determined by the investigators.
193
Statistical Analysis
194
Unless otherwise noted, all statistical tests were two-sided and were performed
195
at the 0.05 significance level and type 2 error at 0.20. The primary efficacy
196
analysis was calculated using the treated population (the safety population; ie,
197
all patients who received ≥1 dose of the study drug). The best overall response
198
to treatment by category (CR, PR, stable disease, PD, or not evaluable) was
199
used to classify patients. Two-sided 95% confidence intervals (CIs) were
200
calculated along with CR and PR point estimates. The median time-to-event
201
and 95% CIs were provided for OS, PFS, and DR. A Kaplan-Meier analysis
202
was performed after 80% of patients had completed six cycles of therapy or had
203
progressed. A post-hoc analysis was conducted to examine the ORR to
205 206
cr
us
an
M
d
te
Ac ce p
204
ip t
191
treatment by different subgroups by age, sex, baseline tumor stage, and tumor histology.
Results
207
Patient Disposition and Treatments
208
A total of 49 patients were enrolled in the study from June 2008 to July 2010
209
and received ≥ 1 dose of bavituximab. The mean age of the study population 11
Page 11 of 33
was 53.9 years. The majority of patients (73.5%) had stage IV disease at
211
enrollment. All patients were of South Asian (Indian) ethnicity. Other baseline
212
characteristics of the study population are listed in Table I. The mean number
213
of weekly bavituximab infusions administered during the study was 18.2. The
214
mean number of cycles of carboplatin-paclitaxel was 4.4 each (range 1 to 6).
215
The most common reason for study exit/discontinuation was disease
216
progression (55.1%). Other reasons for study exit/discontinuation were death
217
(14.3%); consent withdrawn (12.2%); lost to follow-up (8.2%); AEs (4.1%);
218
and non-compliance, investigator decision, and other (each occurring in 2.0%).
Ac ce p
te
d
M
an
us
cr
ip t
210
12
Page 12 of 33
Efficacy
220
The ORR for all 49 treated patients was 40.8%, including one patient who
221
achieved a CR and 19 patients who achieved a PR (Table II). The percentage
222
reduction from baseline in target lesion size is shown in Figure 1. Median PFS
223
was 6.0 months (95% CI, 4.3–7.7 months). Seventeen of the responders
224
subsequently experienced PD or died during the study. The median DR was
225
4.9 months (95% CI, 3.9-6.9), and median OS was 12.4 months (95% CI,
226
9.518.7) Figure 2.
227
The post-hoc analysis of ORR by subgroups is shown in Figure 3. Possibly
228
due to small sample size, the ORR did not deviate significantly from that
229
observed in the total study population for any subgroup analyzed.
230
Safety
231
235
Ac ce p
236
reported AEs with grade 4 severity were hyponatremia (4.1%), infection,
237
anemia, and neutropenia (2.0% each). SAEs were reported in 38.8% of
238
patients. In seven patients (14.3%), the SAE was considered to be study drug-
232 233 234
te
d
M
an
us
cr
ip t
219
A total of 44 patients (89.8%) experienced ≥ 1 AE (Table 3). The most frequently occurring AEs were pyrexia (30.6%), diarrhea (28.6%), alopecia (26.5%), anemia (26.5%), and asthenia (22.4%). By severity, 22.4% of AEs were grade 3, and 6.1% were grade 4. The most common AEs with grade 3 severity were asthenia (10.2%), hypokalemia, and anemia (6.1% each). The
13
Page 13 of 33
related. Anemia, the most common treatment-related SAE, occurred in three
240
patients (6.1%). Hematologic toxicities were within the expected range for a
241
population of patients with advanced NSCLC receiving treatment with
242
paclitaxel and carboplatin [30,31].
243
Activated partial thromboplastin time (aPTT), prothrombin time (PT), and D-
244
dimer were shifted from normal at baseline to high in 42.2%, 62.2%, and 20.0%
245
of patients, respectively. The majority (95.6%) of transiently elevated aPTT
246
values were grade 1 (ie, > ULN to 1.5 x ULN) severity with grade 2 (> 1.5 x
247
ULN to 2.5 x ULN) and grade 3 (>2.5 ULN) elevations occurring in one patient
248
each, without any bleeding. Prolongation of aPTT in human plasma with
249
bavituximab has been attributed to in vitro assay interference with
250
phospholipid-dependent activation of plasma coagulation, which was confirmed
251
via extensive coagulation assessments in a phase I clinical trial of bavituximab
253 254 255
cr
us
an
M
d
te
Ac ce p
252
ip t
239
in refractory advanced solid tumors [22]. Eight patients (16.3%) died during the study; five of these deaths were considered by the investigator to be unrelated to study treatment. Two of these patients died from a convulsion, one of a of snake bite, one of dyspnea, and one
256
from an unknown cause.
257
Three of these deaths were considered by the investigator to be possibly or
258
probably related to study treatment. Two patients (4.1%) died due to 14
Page 14 of 33
myocardial infarction (MI). One of these patients had, however, discontinued
260
the study treatment 69 days before the event. The third patient (2.0%), who had
261
a large squamous cell NSCLC with cavitation, died due to hemoptysis and
262
aspiration.
263
Discussion
264
Bavituximab is a PS-targeting monoclonal antibody with vascular targeting and
265
immune modulating properties. It has a novel mechanism of action that
266
capitalizes on the tumor-specific distribution of exposed PS. Preclinical studies
267
have demonstrated at least additive effects when bavituximab is combined with
268
various cytotoxic agents and radiation therapy. A phase 1 clinical trial
269
established bavituximab 3 mg/kg weekly as the selected biologic dose.
270
This study evaluated bavituximab in combination with carboplatin-paclitaxel as
275
Ac ce p
te
d
M
an
us
cr
ip t
259
276
outcomes may be inferior to smaller phase II studies—carboplatin-paclitaxel
271 272 273 274
first-line therapy for advanced NSCLC. In this single-arm trial, the ORR was 41%, with median PFS of 6.0 months and median OS of 12.4 months. From this experience alone, it is not possible to determine the degree to which the addition bavituximab to carboplatin-paclitaxel may improve clinical outcomes. In recent large phase III advanced NSCLC trials—a setting where clinical
15
Page 15 of 33
has demonstrated radiographic response rates ranging 15-27%, median PFS
278
ranging 3.1-5.8 months, and median OS 8.1-11.2 months [5,9,29,32,33].
279
This clinical trial was conducted entirely in India. The relatively young age of
280
our study cohort (mean 54 years) is comparable to that of other recent lung
281
cancer clinical trials conducted in India [29,34] and reflects the younger age at
282
diagnosis in that region. This may reflect distinct smoking habits of the Indian
283
population; for example smoking bidi (aged Indian tobacco wrapped in a
284
temburni leaf) carries a higher risk of lung cancer than cigarette smoking
285
[35,36]. Other characteristics of lung cancer in India are less clearly defined,
286
such as prevalence of specific oncogenic subtypes (eg, EGFR, ALK). Despite
287
these regional differences, standard lung cancer treatments in India are similar
288
to those in other regions (for instance, platinum doublet therapy as first‐line
289
treatment for advanced NSCLC), and—in clinical trials—outcomes appear
293
Ac ce p
te
d
M
an
us
cr
ip t
277
294
carboplatin-paclitaxel therapy in this population [9]. The incidence of infusion
295
reactions in this study (2%) is comparable to other studies of paclitaxel-
296
containing regimens [32].
290 291 292
comparable to those expected for such regimens [29]. In general, the combination of carboplatin-paclitaxel plus bavituximab appeared to be well tolerated. Gastrointestinal toxicities, fatigue, neuropathy, and hematologic toxicities were observed at rates and severities expected with
16
Page 16 of 33
Potential toxicities of vascular-targeting agents include bleeding, thrombosis,
298
hypertension, proteinuria, wound healing complications, and visceral
299
perforations [9]. In lung cancer trials of the anti-VEGF antibody bevacizumab,
300
vascular-related AEs have been observed [9]. In contrast, in this study and
301
other bavituximab oncology clinical trials, we have not observed hypertension,
302
visceral perforations, or proteinuria [26,37]. Bleeding or thrombosis of any
303
severity were observed in a small proportion of patients (8.2% and 6.1%,
304
respectively) at levels which have been seen in patients with similar cancers
305
[38,39,40]. It is difficult to determine whether the two observed myocardial
306
infarctions were related to bavituximab, as these events could instead reflect
307
common predisposing factors such as dyslipidemia and smoking.
308
One patient developed fatal hemoptysis and aspiration. He was a 56-year-old
309
male who completed three cycles of bavituximab plus paclitaxel-carboplatin
314
Ac ce p
te
d
M
an
us
cr
ip t
297
315
factors could not be determined. In response to this event, future lung cancer
316
clinical trials featuring bavituximab will concentrate on non-squamous NSCLC.
310 311 312 313
followed by five cycles of bavituximab monotherapy. This patient had a large squamous cell tumor encasing the pulmonary artery, as well as progressive tumor cavitation over the course of study treatment, all of which may contribute to bleeding [9,41,42]. Whether the bleeding was driven by histology, the proximity of major vasculature, cavitary changes, or a combination of these
17
Page 17 of 33
On the basis of its proposed mechanism of action (binding the membrane
318
phospholipid PS via complexing with β2GP1), it may be argued that
319
bavituximab conveys a hypothetical risk of antiphospholipid syndrome (APS).
320
This autoimmune disorder is characterized by antiphospholipid antibody
321
production which prolongs aPTT without an increase in bleeding propensity.
322
However, the aPTT prolongation is a dose-dependent in vitro artifact caused by
323
binding of the antiphospholipid antibodies to the phospholipid activator
324
required for clotting.
325
While bavituximab targets exposed PS, its specific mode of action makes a
326
clinical antiphospholipid antibody syndrome highly unlikely. When
327
complexing with β2GP1, bavituximab recognizes domain II in contrast to
328
domain I, in the circular plasma (“non-activated”) conformation of β2GP1 and
329
to a class of anti-β2GP1 antibodies that do not cause thrombosis [43].
334
Ac ce p
te
d
M
an
us
cr
ip t
317
335
population as a whole (29% versus 41%). However, no conclusions can be
336
drawn due to the small number of patients with a squamous or mixed
330 331 332 333
Furthermore, monitoring of D-dimer revealed that 9 (20%) of the patients had a shift from normal at baseline to abnormal high post-baseline without being correlated with any clinical symptoms. In a post-hoc analysis, tumors of squamous or mixed adenosquamous
histology were associated with a decreased ORR compared with the study
18
Page 18 of 33
adenosquamous tumor type (n = 7). A second, phase II study in NSCLC
338
(NCT01160601) was completed that excluded patients with this type of tumor
339
to provide a more homogeneous patient population.
340
It is not possible to compare this single-arm trial with other studies employing
341
vascular targeting agents in combination with chemotherapy for advanced
342
NSCLC. Numerous and vascular targeting agents have been studied for this
343
indication. To date, the anti-VEGF monoclonal antibody bevacizumab, the
344
anti-VEGF receptor monoclonal antibody ramucirumab, and the multitargeted
345
angiokinase inhibitor nintedanib have demonstrated improvements in OS when
346
added to chemotherapy [9,44,45]. However, several other agents targeting the
347
VEGF pathway, including sorafenib, axitinib, cediranib, and others, have failed
348
to achieve this endpoint [46,47,48,49]. It remains to be seen whether the
349
specificity for tumor vasculature and the added mechanism of activating anti-
351 352 353 354 355 356
cr
us
an
M
d
te
Ac ce p
350
ip t
337
tumor immunity of bavituximab will result in more favorable therapeutic and toxicity profiles than these other agents. Thus far, bavituximab does not appear to induce immune-related side effects (eg, colitis, dermatitis, hepatitis, hypophysitis, pneumonitis), as have been seen with antibodies targeting cytotoxic t-lymphocyte antigen 4 (CLTA-4), PD-1, and PD-L1 [12, 13, 14, 15]. In conclusion, the addition of bavituximab to carboplatin-paclitaxel for previously untreated advanced NSCLC demonstrated potential efficacy. The
19
Page 19 of 33
regimen did not appear to enhance chemotherapy-associated toxicities. Nor
358
was bavituximab associated with hypertension, proteinuria, or autoimmune
359
events. The low rate of possible vascular events is not clearly related to
360
bavituximab and warrants follow-up in future studies.
cr
ip t
357
Acknowledgements
363
Conflict of Interest Statement:
364
Raghunadharao Digumarti, MD, P.P. Bapsy, MD, AVS Suresh, MD, G.S.
365
Bhattacharyya, MD, and Lokanatha Dasappa, MD have no financial interests or
366
relationships requiring disclosure. David E. Gerber, MD, has received research
367
funding from Peregrine Pharmaceuticals. Joseph Shan, MPH, is employed by
368
and owns stock in Peregrine Pharmaceuticals.
369
373 374
submit for publication.
375
Editorial and Medical Writer Assistance:
370 371 372
te
d
M
an
362
Ac ce p
us
361
Funding source:
This study was supported by Peregrine Pharmaceuticals, Inc. Role of sponsors:
Peregrine Pharmaceuticals, Inc. participated in the study design; collection, analysis, and interpretation of the data; writing of the report; and the decision to
20
Page 20 of 33
Medical writing and editorial services were provided by Deshawnt Jelani,
377
PharmD of Peregrine Pharmaceuticals, Inc.
Ac ce p
te
d
M
an
us
cr
ip t
376
21
Page 21 of 33
REFERENCES
Ac ce p
te
d
M
an
us
cr
ip t
1. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004;22:777-84 2. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol. 2004;22:785-94. 3. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and GC chemotherapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2004;22 suppl 14:619s. 4. Herbst RS, Prager D, Hermann R, Fehrenbacher L, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:5892-9. 5. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:1835-42. 6. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 2008;26:1871-8. 7. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol. 2012;13:33-42. 8. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:918-27. 9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-50. 10. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21:1804-9. 11. Lorusso PM, Boerner SA, Hunsberger S. Clinical development of vascular disrupting agents: what lessons can we learn from ASA404? J Clin Oncol. 2011;29:2952-5. 12. Zielinski C, Knapp S, Mascaux C, et al. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol. 2013;24:1170-9. 13. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-54. 14. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167-75. 15. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-65. 22
Page 22 of 33
Ac ce p
te
d
M
an
us
cr
ip t
16. Balasubramanian K, Schroit AJ. Aminophospholipid asymmetry: A matter of life and death. Annu Rev Physiol. 2003;65:701-34. 17. Ran S, Downes A, Thorpe PE. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002;62:6132-40. 18. Luster TA, He J, Huang X, et al. Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J Biol Chem. 2006;281:29863-71. 19. Ran S, He J, Huang X, Soares M, et al. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin Cancer Res. 2005;11:1551-62. 20. Yin Y, Huang X, Lynn KD, Thorpe PE. Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation. Cancer Immunol Res. 2013;1:256-68. 21. Beck AW, Luster TA, Miller AF, et al. Combination of a monoclonal antiphosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. Int J Cancer. 2006 May 15;118(10):2639-43. 22. Gerber DE, Stopeck AT, Wong L, et al. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2011;17:6888-96. 23. He J, Luster TA, Thorpe PE. Radiation-enhanced vascular targeting of human lung cancers in mice with a monoclonal antibody that binds anionic phospholipids. Clin Cancer Res. 2007 Sep 1;13(17):5211-8. 24 He J, Yin Y, Luster TA, et al. Antiphosphatidylserine antibody combined with irradiation damages tumor blood vessels and induces tumor immunity in a rat model of glioblastoma. Clin Cancer Res. 2009 Nov 15;15(22):6871-80. 25. Yin Y, Thorpe PE. Targeting phosphatidylserine to improve androgen deprivation therapy of prostate cancer. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract 621. 26. Tabagari J, Nemsadze G, Janjalia M, et al. Phase II study of bavituximab plus docetaxel in locally advanced or metastatic breast cancer. J Clin Oncol 2010; 28 suppl 15:1042. 27. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000 Mar 27;160(6):809-15. 28. Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 Feb 9;293(6):715-22. 29. Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2011 Jun;6(6):1098-103. 30. Bristol-Myers Squibb: Paraplatin (carboplatin) for injection, prescribing information, 2010. 31. Bristol-Myers Squibb: Taxol (paclitaxel) injection, prescribing information, 2011. 23
Page 23 of 33
Ac ce p
te
d
M
an
us
cr
ip t
32. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-8. 33. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-celllung cancer: final results of a phase III trial. J Clin Oncol. 2012 Jun 10;30(17):2055-62. 34. Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol. 2011 Nov 1;29(31):4129-36. 35. Parikh P, Chang AY, Nag S, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol. 2008 Apr;3(4):380-5. 36. Jindal SK, Behera D. Clinical Spectrum Of Primary Lung Cancer-Review Of Chandigarh Experience Of 10 Years. Lung India. 1990;8(2):94-98. 37. Jain M, Raizada N, Kuttan R, et al. Phase II study of bavituximab plus paclitaxel and carboplatin in locally advanced or metastatic breast cancer: interim results. J Clin Oncol 2010; 25 suppl 15;1062. 38. Wall JG, Weiss RB, Norton L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med. 1989;87:501-4. 39. Sack GH Jr, Levin J, Bell WR. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore). 1977;56(1):1-37. 40. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist. 2004;9:561-70. 41. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:218491. 42. Ito M, Niho S, Nihei K, et al. Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy. BMC Cancer. 2012;12:27. 43. Agar C, van Os GM, Mörgelin M, et al. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010;116:1336-43. 44. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014 Jun 2. pii: S0140-6736(14)60845-X. 45. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014 Feb;15(2):143-55.
24
Page 24 of 33
Ac ce p
te
d
M
an
us
cr
ip t
46. Heymach JV, Paz-Ares L, De Braud F, et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:5407-15. 47. Laurie SA, Arnold A, Shepherd FA. Randomized, double-blind Phase II trial of carboplatin plus paclitaxel (C+P) with either daily oral cediranib, an inhibitor of vascular endothelial growth factor receptor (VEGFR) tyrosine kinases, or placebo, in advanced non-small cell lung cancer (NSCLC): a study of the national cancer institute of canada clinical trials group. Ann Oncol 2008;19:abstr 231 PD. 48. Scagliotti G, von Pawel J, Reck M, et al. Sorafenib plus carboplatin/paclitaxel in chemonaive patients with stage IIIB-IV non-small cell lung cancer (NSCLC): interim analysis (IA) results from the phase III, randomized, double-blind, placebo-controlled, ESCAPE (Evaluation of Sorafenib, Carboplatin, and Paclitaxel Efficacy in NSCLC) trial. J Thor Oncol. 2008;3:S97. 49. Garon EB, Kabbinavar F, Neidhart JA. Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): the FALCON trial. J Clin Oncol 2010;28:abstr 7587.
25
Page 25 of 33
Figure Legends Figure 1. Percent reduction in sum of the longest diameters (SLD) of target lesions from baseline (all treated patients). Dashed line represents the 30% threshold for a Response
ip t
Evaluation Criteria in Solid Tumors (RECIST) clinical response. Figure 2. Kaplan-Meier (KM) curve for overall survival (all treated patients).
cr
Figure 3. Forest plot of response rates for subgroups of interest. Dashed line represents the
us
observed response rate of the study population as a whole. The plots for subgroups represent the mean relative risk (RR) ± 1 standard error (SE); Resp, partial and complete responders; BSLD,
Ac ce p
te
d
M
an
sum of largest diameters at baseline, cm
26
Page 26 of 33
Highlights • Bavituximab with paclitaxel/carboplatin is well-tolerated with clinical activity • Encouraging 41% response rate, 6.0 month PFS and 12.4 month OS in advanced NSCLC
Ac ce p
te
d
M
an
us
cr
ip t
We intend to deliver the remaining highlights offline.
27
Page 27 of 33
us
cr
i
Figure 1
Ac
ce pt
ed
M an
Figure 1. Tumor Response
Page 28 of 33
us
cr
i
Figure 2
Ac
ce pt
ed
M an
Figure 2. Overall Survival
Page 29 of 33
us
cr
i
Figure 3
Ac
ce pt
ed
M an
Figure 3. Subgroup Analysis
Page 30 of 33
Characteristic Age, years, mean (SD)
Asian (Indian)
ce pt
Weight, kg, mean (SD)
All Treated Patients
ed
Race, n (%)
M an
Table I. Demographics and Baseline Characteristics
us
cr
i
Table 1
(N = 49) 53.9 (10.8)
49 (100.0)
55.0 (10.9) 1.5 (0.2)
ECOG Performance Status (0/1/2)
2/47/0
Gender (male/female)
35/14
Ac
Body surface area, m2, mean (SD)
Tumor stage at entry, n (%) Stage III
13 (26.5)
Stage IV
36 (73.5)
Abbreviations: ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
Page 31 of 33
M an
Table II. Best Overall Tumor Response by RECIST
us
cr
i
Table 2
ed
ce pt
Complete response
Stable disease
Response, N (%, 95% CI) 20 (40.8, 27.0-55.8)
Overall response rate
Partial response
All Treated Patients (N = 49)
1 (2.0, 0.1-10.9) 19 (38.8, 25.2-53.8) 16 (32.7, 19.9-47.5) 4 (8.2, 2.3-19.6)
Not evaluable or missing
9 (18.4, 8.8-32.0)
Ac
Progressive disease
Abbreviations: CI, confidence interval; RECIST, Response Evaluation Criteria in Solid Tumors. Note: The overall response rate is defined as complete response plus partial response.
Page 32 of 33
us
cr
i
Table 3
M an
Table III. Summary of Adverse Events
All Treated Patients (N = 49) Grade 3 AEs (%)
Grade 4 AEs (%)
11 (22.4)
3 (6.1)
0 (0.0)
0 (0.0)
2 (4.1)
0 (0.0)
ed
Parameter
13 (26.5)
0 (0.0)
0 (0.0)
10 (20.4)
1 (2.0)
0 (0.0)
7 (14.3)
1 (2.0)
0 (0.0)
5 (10.2)
0 (0.0)
0 (0.0)
5 (10.2)
1 (2.0)
0 (0.0)
5 (10.2)
0 (0.0)
0 (0.0)
11 (22.4)
5 (10.2)
0 (0.0)
3 (6.1)
3 (6.1)
0 (0.0)
13 (26.5)
3 (6.1)
1 (2.0)
4 (8.2)
2 (4.1)
1 (2.0)
3 (6.1)
1 (2.0)
2 (4.1)
1 (2.0)
0 (0.0)
1 (2.0)
Total, N (%) Patients with ≥1 AE
44 (89.8) 15 (30.6)
Pyrexia
14 (28.6)
Diarrhea Alopecia Neuropathy
ce pt
Vomiting Paresthesia Anorexia
Asthenia
Ac
Fatigue
Hypokalaemia Anaemia Neutropenia
Hyponatraemia Infection
Abbreviations: AE, adverse event Page 33 of 33